Psma-pet to guide prostatectomy: can psma-pet appropriately modify surgery, reduce nerve damage and optimize quality-of-life?

Active Project Grant Awarded Last action

Award ID
R01CA258994
Recipient
Awarding agency
Obligated
$7,256,773

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 93% complete
Place of performance
Indianapolis, IN 46202, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The 68GA-P16-093 radiopharmaceutical is an investigational agent that targets prostate specific membrane antigen (psma), which is highly expressed in most prostate cancers. Psma-pet has not been validated as a tool for guiding surgical resection of primary prostate cancer. The objective of this phase II clinical trial is to critically test the ability of 68GA-P16-093 pet to identify extra- prostatic extension of prostate cancer, to guide surgical resection, and to improve the patient's post-surgical quality-of-life. For prostate cancer patients who require prostatectomy, we hypothesize that psma-pet findings will accurately differentiate patients who can safely undergo nerve-sparing and/or muscle-sparing surgery from those in whom more aggressive wide resection is essential for cancer control; thus, optimizing quality-of-life outcomes. Therefore, the project has two complementary yet independent specific aims: aim 1. To measure the accuracy of both 68GA-P16-093 pet-CT, and conventional standard-of-care mpmri, for presurgical detection of extra-prostatic extension. Aim 2. To measure treatment modifications, and patient quality-of-life outcomes, that result from 68GA- P16-093 -pet incorporation into surgical planning. The innovations of this project are the application of this imaging technology in pre-surgical treatment planning for newly diagnosed disease; the definitive assessment of agent performance in a surgical randomized controlled trial; and the detailed assessments of imaging impact on both surgical planning and subsequent patient clinical outcome. As a control group, one-half of the enrolled subjects will receive their standard-of-care prostatectomy with surgical planning supported only by multiparametric MRI and biopsy findings. The other half of the subjects will be randomized to also receive pre-surgical pelvic imaging with 68GA-P16-093 pet/CT for independent assessment of the location and extent of disease. The radiology MRI and pet readers will be blinded to the findings of the other modality. The surgeon will receive reports on all imaging, but must document a standard-of-care surgical plan before receiving the pet findings. The surgeon will then document whether, and how, the pet information modifies their prior surgical plan. For validation of imaging findings, whole mount pathology will serve as the "gold standard" for characterization of disease. Patient outcome measures, and cancer recurrence, will be tracked for 18-months following surgery. Our preliminary studies indicate 68GA-P16-093 pet-CT will show higher accuracy than mpmri for detection of extra-prostatic extension. And, that the pet-directed surgical modifications will frequently result in appropriate preservation of nerves and muscle, thereby improving post-treatment quality-of-life for many patients, while also helping to avoid positive surgical margins.

Transactions

Action Obligated Date
Amendment $38,367
Amendment $345,316
Amendment $345,316
Amendment $60,289
Amendment $60,289
Amendment $542,612
Amendment $542,612
Amendment $30,146
Amendment $30,146
Amendment $30,146
Amendment $542,612
Amendment $542,612
Amendment $542,612
Amendment $542,612
Amendment $595,230
Amendment $595,230
Amendment $595,230
Amendment $637,698
Original award $637,698
Show all 19

Subawards

Subrecipient Amount Awarded
Five Eleven Pharma Inc. As described in the proposed project budget, in support of this research effort Five Eleven Pharma agrees to enter into a subcontract from Indiana University… $31,224
Five Eleven Pharma Inc. $34,347

Quick answers

Who received award R01CA258994?

R01CA258994 was awarded to Trustees Of Indiana University by National Cancer Institute (National Institutes of Health) on March 1, 2022.

How much is award R01CA258994 worth?

$7,256,773 has been obligated on R01CA258994.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login